Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom

International Journal of Technology Assessment in Health Care

Volumn 25, Issue 4, 2009, Pages 470-478

  Tappenden, Paul ^a   Chilcott, Jim ^a,b   Brennan, Alan ^a   Pilgrim, Hazel ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Health Care Operational Research   (United Kingdom)

Author keywords

Colorectal neoplasms; Cost benefit analysis; Economics; Review literature

Indexed keywords

COLORECTAL CANCER; COLORECTAL NEOPLASMS; COMMON UNDERSTANDING; CONCEPTUAL MODEL; CURRENT PRACTICES; CYTOTOXIC; ECONOMIC EVALUATIONS; ELECTRONIC DATABASE; END-OF-LIFE; METASTATIC DISEASE; SURGICAL PROCEDURES; SYSTEMATIC REVIEW; UNITED KINGDOM;

COST EFFECTIVENESS; DIAGNOSIS; TUMORS;

COST BENEFIT ANALYSIS;

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; RALTITREXED; UFT; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CANCER THERAPY; COLON CANCER; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FOLLOW UP; HEALTH CARE COST; HUMAN; LIVER METASTASIS; MEDICAL DECISION MAKING; PALLIATIVE THERAPY; REVIEW; SIGMOIDOSCOPY; SYSTEMATIC REVIEW; TERMINAL CARE; UNITED KINGDOM; CLINICAL TRIAL; COLORECTAL TUMOR; COST; ECONOMICS; OCCULT BLOOD; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COSTS AND COST ANALYSIS; GREAT BRITAIN; HUMANS; OCCULT BLOOD; OUTCOME ASSESSMENT (HEALTH CARE); PALLIATIVE CARE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SIGMOIDOSCOPY;

EID: 74049090140     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309990407     Document Type: Review

References (50)

1. Aballea S, Boler A, Craig A,Wasan H. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom. Eur J Cancer. 2007;43:1687-1693.
2. Barber MD, Abraham A, Brydon WG, et al. Assessment of faecal occult blood loss by qualitative and quantitative methods. J R Coll Surg Edinb. 2002;47:491-494.
3. Beard SM, Holmes M, Price C, Majeed AW. Hepatic resection for colorectal liver metastases: A cost-effectiveness analysis. Ann Surg. 2000;232:763-776.
4. Brown G, Davies S, Williams GT, et al. Effectiveness of preoperative staging in rectal cancer: Digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? Br J Cancer. 2004;91:23-29.
5. Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: The X-ACT trial. Br J Cancer. 2006;94:1122-1129.
6. Chaudhri S, Brown L, Hassan I, et al. Preoperative intensive, community-based vs. traditional stoma education: A randomized, controlled trial. Dis Colon Rectum. 2005;48:504-509.
7. Chilcott JB, Tappenden P, Rawdin A, et al. Avoiding and identifying errors in health technology assessment models. Health Technol Assess. In press.
8. CunninghamD.Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer. 1998;77(Suppl 2):15-21.
9. Cunningham D, Falk S, Jackson D. Clinical and economic benefits of irinotecan in combinationwith 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Br J Cancer. 2002;86:1677-1683.
10. Daniels K, McKeeM. Options for screening for colorectal cancer in the Royal Air Force: A cost-effectiveness evaluation. J R Army Med Corps. 1995;141:142-150.
11. de Verteuil RM, Hernandez RA, Vale L, et al. Economic evaluation of laparoscopic surgery for colorectal cancer. Int J Technol Assess Health Care. 2007;23:464-472.
12. Durand-Zaleski I, Earlam S, Fordy C, Davies M, Allen-Mersh TG. Cost-effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases. Cancer. 1998;83:882-888.
13. Eccersley AJ,Williams NS.Anorectal reconstruction-restoring continence after abdominoperineal excision of the anorectum. Ital J Gastroenterol Hepatol. 1998;30:549-554.
14. Eggington S, Tappenden P, Pandor A, et al. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer. 2006;95:1195-1201.
15. Franks PJ, Bosanquet N, Thorpe H, et al. Short-term costs of conventional vs laparoscopic assisted surgery in patients with colorectal cancer (MRC CLASICC trial). Br J Cancer. 2006;95:6-12.
16. Hale JP, Cohen DR, Maughan TS, Stephens RJ. Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer. Br J Cancer. 2002;86:1684-1690.
17. Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: Systematic review and economic evaluation. Health Technol Assess. 2008;12:1-182.
18. Iveson TJ, Hickish T, Schmitt C, Van Cutsem E. Irinotecan in second-line treatment of metastatic colorectal cancer: Improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer. 1999;35:1796-1804.
19. Kerr D, O'Connor KM. An economic comparison of the net clinical benefit and treatment costs of raltitrexed and 5- fluorouracil + leucovorin (Mayo regimen) in advanced colorectal cancer. J Med Econ. 1999;2:123-132.
20. King PM, Blazeby JM, Ewings P, et al. Randomized clinical trial comparing laparoscopic and open surgery for colorectal cancer within an enhanced recovery programme. Br J Surg. 2006;93:300-308.
21. King PM, Blazeby JM, Ewings P, et al. The influence of an enhanced recovery programme on clinical outcomes, costs and quality of life after surgery for colorectal cancer. Colorectal Dis. 2006;8:506-513.
22. Lloyd JM, Hummel S, Bansback N, Orr B, Seymour M. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess. 2001;5:1-128.
23. Macafee DAL, Whynes DK, Scholefield JH. Risk-stratified intensive follow up for treated colorectal cancer - Realistic and cost saving? Colorectal Dis. 2008;10:222-230.
24. Maslekar S, Pillinger SH, Sharma A, et al. Cost analysis of transanal endoscopicmicrosurgery for rectal tumours. Colorectal Dis. 2007;9:229-234.
25. Mihai R, Borley N. Transanal endoscopic microsurgery - impact on the practice of a colorectal surgeon in a district general hospital. Ann R Coll Surg Engl. 2005;87:432-436.
26. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008.
27. Neilson AR, Walker A, Forbes D. Evaluation of the UK colorectal cancer screening pilot: Final report. Chapter 5: Health Economics. 92-104. 2003. http://www.cancerscreening.nhs.uk/ bowel/finalreport.pdf (accessed April 15, 2008).
28. Nicholls CJ, Cassidy J, Freemantle N, Harrison M, Carita P. Cost-effectiveness of combination chemotherapy (oxaliplatin or irinotecan in combination with 5-FU/FA) compared with 5-FU/FA alone. J Med Econ. 2001;4:115-125.
29. Nicholls CJ, Cassidy J, Freemantle N, Harrison M, Carita P. Cost-effectiveness of oxaliplatin in combination with 5-FU/FA compared with 5-FU/FA alone. J Med Econ. 2001;4:127-135.
30. Noblett SE, Horgan AF. A prospective case-matched comparison of clinical and financial outcomes of open versus laparoscopic colorectal resection. Surg Endosc. 2007;21:404-408.
31. Poston G, Benjamin IS, Diamond T, et al. Costs of neoadjuvant chemotherapy and surgery in patientswith livermetastases from advanced colorectal cancer. J Med Econ. 2001;4:167-177.
32. Renehan AG, O'Dwyer ST, Whynes DK. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. BMJ. 2004;328:81-84.
33. Robert G, Brown J, Garvican L. Cost of quality management and information provision for screening: Colorectal cancer screening. J Med Screen. 2000;7:31-34.
34. Robinson MH, Marks CG, Farrands PA, et al. Is an immunological faecal occult blood test better than Haemoccult? A costbenefit study. Eur J Surg Oncol 1995;21:261-264.
35. Rowe MW, Valle JW, Swindell R, Fitzsimmons L, James RD. New face for a familiar friend: The deGramont regimen in the treatment of metastatic colorectal cancer given as an outpatient: A feasibility study. J Oncol Pharm Pract. 2002;8:97-103.
36. Starling N, Tilden D, White J, Cunningham D. Costeffectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer. 2007;96:206-212.
37. Tappenden P, Chilcott J, Eggington S, et al. Option appraisal of population-based colorectal cancer screening programmes in England. Gut. 2007;56:677-684.
38. Tappenden P, Jones R, Paisley S, et al. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess. 2007;11:1-128.
39. Tappenden P, Jones R, Paisley S, Carroll C. The costeffectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer. 2007;43:2487-2494. (Pubitemid 350086932)
40. Trueman P, Chilcott JB, Tappenden P, et al. Bowel cancer services: Costs and benefits. 2007. Final report to the Department of Health. http://www.shef.ac.uk/scharr/sections/ heds/modelling/colorectal-cancers.html (accessed February 3, 2008).
41. Vellacott KD, Clarke D, Beech C, Joshi H. Flexible sigmoidoscopy in general practice. Colorectal Dis. 2002;4:123-126.
42. Walker AR,Whynes DK, ThomasWM, et al. Retesting positive results in screening for colorectal cancer: A marginal analysis. Appl Econ. 1993;23:1015-1017.
43. Walker A, Whynes DK, Chamberlain JO, et al. The cost of screening for colorectal cancer. JEpidemiol Community Health. 1991;45:220-224.
44. Walker A, Whynes DK. Filtering strategies in mass population screening for colorectal cancer: An economic evaluation. Med Decis Making. 1992;12:2-7.
45. Walker AR, Whynes DK, Hardcastle JD. Rehydration of guaiac-based faecal occult blood tests in mass screening for colorectal cancer. An economic perspective. Scand J Gastroenterol. 1991;26:215-218.
46. Ward SE, Kaltenthaler E, Cowan J, et al. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer. 2006;95:27-34.
47. Whynes DK. Cost-effectiveness of screening for colorectal cancer: Evidence from the Nottingham faecal occult blood trial. J Med Screen. 2004;11:11-15.
48. Whynes DK,Walker AR, Hardcastle JD. Cost-effective screening strategies for colorectal cancer. J Public Health Med. 1992;14:43-49.
49. Whynes DK, Walker AR, Hardcastle JD, et al. Cost savings in mass population screening for colorectal cancer resulting from the early detection and excision of adenomas. Health Econ. 1992;1:53-60.
50. Whynes DK. Neilson AR,WalkerAR, et al. Faecal occult blood screening for colorectal cancer: Is it cost-effective? Health Econ. 1998;7:21-29.